An activist investor holding a stake in enVVeno Medical Corporation has called on the company’s board to halt clinical spending and allow shareholders to vote on potential strategic alternatives, including liquidation or a merger.
NorthStrive Companies Inc. said its subsidiary NorthStrive Fund II LP, which owns about 5.05% of enVVeno’s outstanding shares, sent an open letter to the board and shareholders urging the company to reconsider its current strategy and hold a special shareholder meeting.
The investor said its call follows a February 20 Schedule 13D filing outlining strategic proposals. According to NorthStrive, enVVeno’s chief executive told the fund during a subsequent call that the board had no plans to pursue those recommendations.
NorthStrive said it strongly disagrees with that position and has prepared a financial model comparing the company’s current strategy with two alternatives: an orderly liquidation of the business and return of capital to shareholders, or a merger or reverse-merger with another company.
The analysis has been provided to the board and posted publicly so investors can evaluate the scenarios, the fund said.
Activist investor questions current strategy
In the letter to the board, NorthStrive highlighted enVVeno’s financial position, noting the company reported roughly $28 million in cash and short-term investments as of September 30, 2025 and has no long-term debt.
However, the company remains pre-revenue and is burning about $16 million annually, which the fund said implies a remaining cash runway of about 20 to 21 months.
The investor argued that pursuing development of another early-stage asset following the recent FDA non-approval of the company’s lead program would expose shareholders to another long and uncertain clinical cycle.
NorthStrive said that in its view the company’s balance sheet has effectively become its most valuable asset and should be used to deliver returns rather than fund new high-risk programs.
The fund also raised concerns about board alignment with shareholders, noting that directors collectively own a relatively small number of shares compared with the company’s total outstanding stock, while holding unexercised options that provide potential upside without immediate capital at risk.
Calls for strategic review and shareholder vote
NorthStrive is urging the board to take three immediate steps: halt non-essential clinical spending, begin a formal review of strategic alternatives and call a special shareholder meeting so investors can vote on the company’s future direction.
The fund estimates that, based on the company’s most recent financial statements, roughly $28.5 million could potentially be available for distribution after liabilities.
Under a full liquidation scenario, NorthStrive said it estimates proceeds of about $43.47 per share, which it says would represent roughly a 335% upside for shareholders.
The investor argued that such a scenario would rely solely on the company’s existing balance sheet rather than future clinical success or regulatory approvals.
Merger seen as alternative path
If the board does not pursue liquidation, NorthStrive said it should instead consider a merger or reverse merger with a revenue-generating partner.
In that case, the company’s net cash position could become a strategic asset for a potential partner rather than continuing to decline as development spending continues, the fund said.
NorthStrive argued that continuing with the current plan—funding high-risk clinical programs while the company’s cash reserves diminish—offers a weaker risk-reward profile than either liquidation or a strategic transaction.
The investor said it remains willing to work constructively with the board but believes shareholders should ultimately decide the company’s path through a vote at a special meeting.
The information contained herein is based on publicly available information relating to enVVeno Medical Corporation (the “Company”). Except where otherwise indicated, the information in this editorial speaks only as of the date hereof, and NorthStrive Fund II LP undertakes no obligation to update or revise any statements contained herein.
The Letter may include forward-looking statements that reflect current views regarding future events, strategic alternatives, or potential outcomes.
Any financial estimates or projections included herein, including those contained in the financial model referenced in this Letter, are based on assumptions believed to be reasonable but are inherently subject to uncertainty and may not reflect actual outcomes. Shareholders should conduct their own independent analysis and reach their own conclusions regarding the matters discussed herein.
NorthStrive Fund II LP currently beneficially owns securities of the Company. NorthStrive reserves the right to increase or decrease its ownership of Company securities at any time, including through purchases, sales, derivatives, or other transactions, subject to applicable law. NorthStrive also reserves the right to engage in discussions with the Board of Directors, management, shareholders, or other parties regarding strategic alternatives or other matters relating to its investment in the Company.